**BACKGROUND**

Digoxin is a cardiac glycoside that decreases the conduction of electrical impulses through the AV node in the heart. It also increases the force of heart contractions by binding to and inhibiting the Na⁺/K⁺ ATPase pump, which causes an increase in the level of sodium ions in the myocytes, thereby leading to a rise in the level of calcium ions. Digoxin is expressed in the foxglove plant digitalis and is then extracted for clinical use to improve the pumping ability of the heart in congestive heart failure (CHF) and to treat patients with high blood pressure. It is also used to help normalize some dysrhythmias (abnormal types of heartbeat) and to stabilize atrial fibrillation and atrial flutter with rapid ventricular response. Digoxin has a half life of approximately 36 hours with effective plasma levels at 1-2.6 nmol/L.

**REFERENCES**


**SOURCE**

Digoxin (103) is a mouse monoclonal antibody raised against Digoxin.

**PRODUCT**

Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

**APPLICATIONS**

Digoxin (103) is recommended for detection of Digoxin of Digoxin origin by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

**STORAGE**

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

**RESEARCH USE**

For research use only, not for use in diagnostic procedures.

**PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.